Immunotherapy with cells.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cyclophosphamide
/ therapeutic use
Doxorubicin
/ therapeutic use
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse
/ therapy
Middle Aged
Prednisone
/ therapeutic use
Receptors, Chimeric Antigen
/ therapeutic use
Rituximab
/ therapeutic use
Vincristine
/ therapeutic use
Journal
Hematology. American Society of Hematology. Education Program
ISSN: 1520-4383
Titre abrégé: Hematology Am Soc Hematol Educ Program
Pays: United States
ID NLM: 100890099
Informations de publication
Date de publication:
04 12 2020
04 12 2020
Historique:
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
5
5
2021
Statut:
ppublish
Résumé
Both older and newer cell therapies have demonstrated impressive responses in otherwise poor-prognosis lymphomas. Consequently, cellular therapy now plays a major role in the management of many non-Hodgkin lymphomas. In this article, we examine the role of chimeric antigen receptor (CAR) T cells, allogeneic stem cell transplantation, and virus-directed T cells for treatment of lymphomas. We review the current indications for CAR T cells and discuss our clinical approach to selecting and treating patients with aggressive B-cell lymphomas to receive CD19-directed CAR T cells. In addition, we highlight newer cell therapies and provide an overview of promising future approaches that have the potential to transform immunotherapy with cells to treat lymphomas.
Identifiants
pubmed: 33275723
pii: 474334
doi: 10.1182/hematology.2020000174
pmc: PMC7727576
doi:
Substances chimiques
R-CHOP protocol
0
Receptors, Chimeric Antigen
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
590-597Informations de copyright
© 2020 by The American Society of Hematology.
Déclaration de conflit d'intérêts
Conflict-of-interest disclosure: E.A.C. has received honoraria from Juno Therapeutics and Kite Pharma. D.L.P. has received honoraria from Novartis, Kite, Incyte, and Janssen; royalties from Novartis as a patent inventor for CTL019 (CAR T cells for CD19 disease, managed according to University of Pennsylvania patent policy); and research funding from Novartis. His spouse was formerly employed by Genentech.
Références
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Blood. 2019 Dec 12;134(24):2149-2158
pubmed: 31697826
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
J Clin Oncol. 2013 Sep 1;31(25):3100-9
pubmed: 23897963
J Clin Oncol. 2020 Nov 10;38(32):3805-3815
pubmed: 33021872
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Mol Ther. 2017 Oct 4;25(10):2245-2253
pubmed: 28803861
Cancer Immunol Immunother. 2014 Sep;63(9):969-75
pubmed: 24943274
Blood. 2019 Sep 12;134(11):860-866
pubmed: 31320380
J Clin Oncol. 2020 Sep 1;38(25):2862-2871
pubmed: 32298202
Blood Adv. 2020 Jul 28;4(14):3268-3276
pubmed: 32702097
Am J Hematol. 2019 May;94(S1):S50-S54
pubmed: 30632623
Blood. 2016 Mar 3;127(9):1117-27
pubmed: 26813675
J Clin Oncol. 2020 Sep 20;38(27):3119-3128
pubmed: 32401634
J Clin Oncol. 2016 Apr 1;34(10):1112-21
pubmed: 26811520
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321
pubmed: 31446199
Sci Transl Med. 2017 Jan 25;9(374):
pubmed: 28123068
J Clin Invest. 2020 Feb 3;130(2):733-747
pubmed: 31689242
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Blood. 2020 May 7;135(19):1650-1660
pubmed: 32076701
Blood. 2018 Jul 19;132(3):245-253
pubmed: 29699989
J Clin Oncol. 2014 Mar 10;32(8):798-808
pubmed: 24344220
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-1551
pubmed: 27131863
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Blood Adv. 2020 Jul 14;4(13):2871-2883
pubmed: 32589728
Blood. 2012 Nov 15;120(20):4256-62
pubmed: 23007405
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Br J Haematol. 2016 Jul;174(2):235-48
pubmed: 26989808
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
J Clin Oncol. 2011 May 10;29(14):1855-63
pubmed: 21482995
Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31
pubmed: 23333532